Leerink Partners Downgrades HilleVax to Market Perform, Lowers Price Target to $2
Author: Benzinga Newsdesk | July 09, 2024 01:49pm
Leerink Partners analyst David Risinger downgrades HilleVax (NASDAQ:HLVX) from Outperform to Market Perform and lowers the price target from $28 to $2.